FOLH1 and metastatic malignant neoplasm in the lymph nodes: When comparing OS of patients stratified by FOLH1 expression, patients with FOLH1-High tumors displayed significantly longer median OS relative to those with FOLH1-Low tumors (median survival difference of 15.9 months in patients with biopsies derived from primary prostate [HR = 0.71, P < .0001], 11.6 months for lymph node metastases [HR = 0.67, P < .002], and 12.4 months for distant metastatic sites [HR = 0.61, P < .0001]) (Figure 5A-C), suggesting FOLH1 is a positive prognostic factor.